Valion Bio, Inc.
VBIO· Nasdaq
VBIOValion Bio, Inc.
Filed Mar 31, 2023 · 10-K · 90 days after period end · 0000950170-23-011359
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|
| Revenue | $407.00K | $389.00K |
| Net Income | -$2.25M | -$3.72M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end
